Sandro Iannaccone

Sandro Iannaccone

Auto-generated profile, based on publicly available information

Sandro Iannaccone

Department of Clinical Neuroscience, San Raffaele Hospital, Milan, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
SIS. Iannaccone
S. Iannaccone
CCC. Cerami
C. Cerami
MAMassimo Alessio
Massimo Alessio
Valentina GaribottoValentina Garibotto
Valentina Garibotto
APA. Panzacchi
A. Panzacchi
DPD. Perani
D. Perani
Reactive microgliosis, hallmark of neuroinflammation, may contribute to neuronal degeneration, as shown in several neurodegenerative diseases. We in vivo evaluated microglia activation in early dementia with Lewy bodies, still not reported, and compared with early Parkinson's disease, to assess possible differential pathological patterns. We measured the [(11)C]-PK11195 binding potentials with Positron Emission Tomography, using a simplified reference tissue model, as marker of microglia activation, and cerebral spinal fluid protein carbonylation levels, as marker of oxidative stress. Six dementia with Lewy bodies and 6 Parkinson's disease patients within a year from the onset, and eleven healthy controls were included. Clinical diagnosis was confirmed at a 4-year follow-up. In dementia with Lewy bodies as well as in Parkinson's disease, we found significant (p < 0.001) [(11)C]-PK11195 binding potential increases in the substantia nigra and putamen. Patients with Lewy bodies dementia had extensive additional microglia activation in several associative cortices. This was evident also at a single subject level. Significant increase of Cerebral Spinal Fluid protein carbonylation was shown in both patients' groups. [(11)C]-PK11195 Positron Emission Tomography imaging revealed neuroinflammation in dementia with Lewy bodies and Parkinson's disease, mirroring, even at a single subject level, the common and the different topographical distribution of neuropathological changes, yet in the earliest stages of the disease process. Focusing on those events that characterize parkinsonisms and Parkinson's disease may be the key to further advancing the understanding of pathogenesis and to taking these mechanisms forward as a means of defining targets for neuroprotection.

1 January 2018 in NeuroImage: Clinical
Verified
Journal Article
Open access
SCSilvia Paola Caminiti
Silvia Paola Caminiti
TBTommaso Ballarini
Tommaso Ballarini
ASArianna Sala
Arianna Sala
CCChiara Cerami
Chiara Cerami
LPLuca Presotto
Luca Presotto
ESElio Scarpini
Elio Scarpini
In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias. We included 80 MCI subjects with neurological and neuropsychological assessments, FDG-PET scan and CSF measures at entry, all with clinical follow-up. FDG-PET data were analysed with a validated voxel-based SPM method. Resulting single-subject SPM maps were classified by five imaging experts according to the disease-specific patterns, as "typical-AD", "atypical-AD" (i.e. posterior cortical atrophy, asymmetric logopenic AD variant, frontal-AD variant), "non-AD" (i.e. behavioural variant FTD, corticobasal degeneration, semantic variant FTD; dementia with Lewy bodies) or "negative" patterns. To perform the statistical analyses, the individual patterns were grouped either as "AD dementia vs. non-AD dementia (all diseases)" or as "FTD vs. non-FTD (all diseases)". Aβ42, total and phosphorylated Tau CSF-levels were classified dichotomously, and using the Erlangen Score algorithm. Multivariate logistic models tested the prognostic accuracy of FDG-PET-SPM and CSF dichotomous classifications. Accuracy of Erlangen score and Erlangen Score aided by FDG-PET SPM classification was evaluated. The multivariate logistic model identified FDG-PET "AD" SPM classification (Expβ = 19.35, 95% C.I. 4.8-77.8, p < 0.001) and CSF Aβ42 (Expβ = 6.5, 95% C.I. 1.64-25.43, p < 0.05) as the best predictors of conversion from MCI to AD dementia. The "FTD" SPM pattern significantly predicted conversion to FTD dementias at follow-up (Expβ = 14, 95% C.I. 3.1-63, p < 0.001). Overall, FDG-PET-SPM classification was the most accurate biomarker, able to correctly differentiate either the MCI subjects who converted to AD or FTD dementias, and those who remained stable or reverted to normal cognition (Expβ = 17.9, 95% C.I. 4.55-70.46, p < 0.001). Our results support the relevant role of FDG-PET-SPM classification in predicting progression to different dementia conditions in prodromal MCI phase, and in the exclusion of progression, outperforming CSF biomarkers.

14 June 2015 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
ADAlessandra Dodich
Alessandra Dodich
CCChiara Cerami
Chiara Cerami
NCNicola Canessa
Nicola Canessa
CCChiara Crespi
Chiara Crespi
SISandro Iannaccone
Sandro Iannaccone
SCStefano F. Cappa
Stefano F. Cappa

1 April 2020 in Journal of Rehabilitation Medicine
Verified
Journal Article
Closed access
LBLuigia Brugliera
Luigia Brugliera
ASAlfio Spina
Alfio Spina
PCP Castellazzi
P Castellazzi
PCP Cimino
P Cimino
ATAndrea Tettamanti
Andrea Tettamanti
SIS Iannaccone
S Iannaccone

1 January 1995 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
SISandro Iannaccone
Sandro Iannaccone
MZMarco Zucconi
Marco Zucconi
PMPaolo Marchettini
Paolo Marchettini
LSLuigi Ferini Strambi
Luigi Ferini Strambi
RNRaffaello Nemni
Raffaello Nemni
SSSalvatore Smirne
Salvatore Smirne

23 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FAFederica Alemanno
Federica Alemanno
EHElise Houdayer
Elise Houdayer
DEDaniele Emedoli
Daniele Emedoli
MLMatteo Locatelli
Matteo Locatelli
PMPietro Mortini
Pietro Mortini
SISandro Iannaccone
Sandro Iannaccone
Chronic pain, such as low-back pain, can be a highly disabling condition degrading people’s quality of life (QoL). Not every patient responds to pharmacological therapies, thus alternative treatments have to be developed. The chronicity of pain can lead to a somatic dysperception, meaning a mismatch between patients’ own body perception and its actual physical state. Since clinical evaluation of pain relies on patients’ subjective reports, a body image disruption can be associated with an incorrect pain rating inducing incorrect treatment and a possible risk of drug abuse. Our aim was to reduce chronic low-back pain through a multimodal neurorehabilitative strategy using innovative technologies to help patients regain a correct body image. Twenty patients with chronic low-back pain were included. Before and after treatment, patients underwent: a neurological exam; a neuro-psychological evaluation testing cognitive functions (memory, attention, executive functions) and personality traits, QoL and mood; pain ratings; sensorimotor functional abilities’ testing. Patients underwent a 6 week-neurorehabilitative treatment (total 12 sessions) using virtual reality (VRRS system, Khymeia, Italy). Treatment consisted on teaching patients to execute correct movements with the painful body parts to regain a correct body image, based on the augmented multisensory feedback (auditory, visual) provided by the VRRS. Our data showed significant reductions in all pain rating scale scores (p<0.05); significant improvements of QoL in the domains of physical functioning, physical role functioning, bodily pain, vitality, and social role functioning; improvements in cognitive functions (p<0.05); improvements in functional scales (p<0.05) and mood (p = 0.04). This non-pharmacological approach was able to act on the multi-dimensional aspects of pain and improved patients’ QoL, pain intensity, mood and patient’s functional abilities.